This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to obtain preliminary safety data of the device, KC-002, containing cultured human keratinocytes (skin cells) applied externally to a diabetic foot ulcer to promote wound healing. The proof of principal, that there is reduction in wound area, means that the KC-002 device represents a means for supplying a milieu of factors from living keratinocytes to promote wound healing in a dressing form that is removable. It is estimated that 15 percent of patients with diabetes will develop foot ulcers and that 15 <ETH> 20 percent of those will progress to lower-extremity amputation. The cost of treating diabetic foot ulcers is estimated at $28,000 over the first two years after diagnosis. The cost of amputation ranges from $20,000 to $60,000 yet it has been estimated that 85% of these amputations could be prevented. There is a need for more effective therapies which will address the deficiencies that underlie the chronic wound. Recently, clinical therapies that include the use of skin substitutes and growth factors have demonstrated that human skin cells placed on a diabetic wound induce the natural healing process. The interactive wound dressing device (KC-002) is placed on the target ulcer and removed after 7 days. All ulcers will be on the bottom of the foot and must have been present for at least 30 days. The ulcer must be free of infection, vascular disease and must not be currently treated with growth factors. The study population includes patients 18 years and older of either sex and any racial/ethnic background who have presented to the University of Michigan Wound Care Clinic a neuropathic diabetic foot ulcer and meet the inclusion/exclusion criteria. The primary outcome being evaluated is that there are no safety or sensitization problems resulting from the use of a dressing consisting of human skin cells grown on microcarrier beads in patients with diabetic foot ulcers. A secondary outcome is that there is reduction in the size of the ulcer.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000042-46
Application #
7376545
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2006-04-05
Project End
2007-02-28
Budget Start
2006-04-05
Budget End
2007-02-28
Support Year
46
Fiscal Year
2006
Total Cost
$78,178
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Law, Ian H; Alam, Osman; Bove, Edward L et al. (2016) Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation. Circ Arrhythm Electrophysiol 9:
Schrepf, Andrew; Harper, Daniel E; Harte, Steven E et al. (2016) Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain 157:2217-2225
As-Sanie, Sawsan; Kim, Jieun; Schmidt-Wilcke, Tobias et al. (2016) Functional Connectivity is Associated With Altered Brain Chemistry in Women With Endometriosis-Associated Chronic Pelvic Pain. J Pain 17:1-13

Showing the most recent 10 out of 1380 publications